MarketCapExport financials
vTv Therapeutics (VTVT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
vTv Therapeutics Income Statement 2025-2011 | VTVT
Brief overview of income trends at vTv Therapeutics
The overview follows changes across a five-year period. vTv Therapeutics reported revenue of 2.8 million dollars in 2019 and 1 million dollars by 2024. The total change was −63.2%, with a CAGR of approximately −18.1%. The decline points to a contraction in the scale of the business.
EBITDA changed from −$20.9 million to −$24.1 million (−15.5%). Operating profitability strengthened faster than the scale of sales. EBITDA margin moved from −754.5% to −2368.8%. A lower EBITDA share weakens the quality of the result.
Across the five years, the net result shifted from −13 million dollars to −18.5 million dollars. The period ended with a larger loss than it began with.
Overall conclusion
Signs of deterioration dominate the five-year picture. The main areas of concern are declining net profitability, pressure on operating profitability and a low EBITDA margin. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement vTv Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | - | - | - | - | 67.6 M | 34.4 M | 75 M | 53.8 M | 60 M | - | - | - | - |
Shares |
- | - | - | - | - | - | 30.3 M | 12.4 M | 9.69 M | 9.55 M | 8.28 M | - | - | - | - |
Historical Prices |
16.5 | 22 | 33.6 | 0.87 | 0.995 | 1.86 | 1.7 | 2.65 | 6.01 | 4.83 | 6.81 | - | - | - | - |
Net Income |
-27 M | -18.5 M | -20.2 M | -19.2 M | -13 M | -8.5 M | -13 M | -7.91 M | -16.1 M | -16.4 M | -27.5 M | -36.1 M | -48.2 M | - | - |
Revenue |
- | 1.02 M | - | 2.02 M | 4 M | 6.41 M | 2.76 M | 12.4 M | 291 K | 634 K | 519 K | 1.55 M | 976 K | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | 519 K | 1.55 M | 976 K | - | - |
Operating Income |
-32.8 M | -24.2 M | -25.5 M | -22.5 M | -21.7 M | -11.9 M | -20.9 M | -19.8 M | -50.7 M | -55 M | -38.1 M | -28.9 M | -35.8 M | - | - |
Interest Expense |
- | - | 13 K | 15 K | 12 K | 692 K | 1.83 M | 3.29 M | 3.09 M | 398 K | 108 K | 286 K | 476 K | - | - |
EBITDA |
-32.8 M | -24.1 M | -25.4 M | -22.4 M | -21.6 M | -11.8 M | -20.9 M | -19.6 M | -50.5 M | -54.8 M | -37.6 M | -28 M | -34.7 M | - | - |
Operating Expenses |
32.8 M | 25.2 M | 25.5 M | 24.6 M | 25.7 M | 18.3 M | 23.7 M | 32.3 M | 51 M | 55.7 M | 38.7 M | 30.4 M | 36.8 M | - | - |
General and Administrative Expenses |
14.9 M | 13.7 M | 11.9 M | 12.2 M | 12.3 M | 7.25 M | 8.54 M | 9.22 M | 11.3 M | 9.91 M | 9.08 M | 11.7 M | 11.4 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement vTv Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income |
-11.6 M | -13.1 M | 24.1 M | -7.14 M | -8.7 M | -6.05 M | -5.09 M | -3.63 M | -4.78 M | -5.18 M | -4.86 M | -3.48 M | -6.65 M | -5.62 M | -4.5 M | -4.74 M | -4.26 M | -3.15 M | -7.01 M | -7.05 M | -1.09 M | -608 K | -4.24 M | 1.13 M | -1.53 M | -3.37 M | -4.72 M | -5.03 M | -4.12 M | -2.88 M | -5.88 M | -1.83 M | -796 K | -3.07 M | -2.95 M | -4.31 M | -3.65 M | -3.96 M | -4.22 M | -13.7 M | -13.5 M | -14.6 M | -13.5 M | -11.1 M | -9.82 M | -10.4 M | -9.81 M | -7.72 M | -5.87 M | -7.4 M | -15.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | 36.8 M | - | - | - | - | 17 K | - | - | 1 M | - | - | - | - | 9 K | - | 9 K | 2 M | 9 K | 3 M | 9 K | 987 K | 6.4 M | 7 K | 8 K | 8 K | 7 K | 8 K | 1.83 M | 921 K | 4.52 M | 3.38 M | 2.47 M | 2.06 M | 233 K | 15 K | 13 K | 30 K | 38 K | 38 K | 182 K | 376 K | 226 K | 133 K | 110 K | 50 K | 934 K | 400 K | 201 K | 14 K | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-12.4 M | -13.9 M | 23.3 M | -7.88 M | -10.7 M | -7.72 M | -6.5 M | -4.89 M | -6.51 M | -7.16 M | -5.63 M | -4.71 M | -5.37 M | -8 M | -7.43 M | -6.34 M | -5.69 M | -4.03 M | -6.48 M | -11.1 M | -1.6 M | -4.67 M | -4.28 M | 1.83 M | -2.83 M | -4.2 M | -6.65 M | -6.39 M | -5.42 M | -4.79 M | -4.29 M | -351 K | -1.48 M | -8.86 M | -9.13 M | -12.8 M | -11.5 M | -12.6 M | -13.8 M | -13.3 M | -13.5 M | -14.6 M | -13.5 M | -11.1 M | -9.44 M | -7.89 M | -9.72 M | -6.67 M | -5.52 M | -7.19 M | -9.52 M | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | -3.29 M | 4 K | 2 K | 1.79 M | -618 K | 403 K | -167 K | -3.23 M | 634 K | -1.08 M | 2.9 M | - | - | 235 K | 222 K | 168 K | - | 404 K | 1 K | 626 K | - | 10 K | 870 K | 36 K | 852 K | 849 K | 832 K | 559 K | -24 K | 2 K | 1 K | -1 K | 13 K | -1 K | -1.51 M | 660 K | - | -25 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-12.4 M | -13.9 M | 23.3 M | -7.88 M | -10.7 M | -7.72 M | -6.49 M | -4.87 M | -6.48 M | -7.13 M | -5.6 M | -4.68 M | -5.35 M | -7.98 M | -7.4 M | -6.32 M | -5.66 M | -4 M | -6.46 M | -11.1 M | -1.58 M | -4.65 M | -4.26 M | 1.85 M | -2.76 M | -4.16 M | -6.62 M | -6.37 M | -5.42 M | -4.78 M | -4.28 M | -244 K | -1.37 M | -8.78 M | -9.09 M | -12.7 M | -11.5 M | -12.6 M | -13.7 M | -13.3 M | -13.5 M | -14.6 M | -13.5 M | -11 M | -9.08 M | -7.64 M | -9.59 M | -6.67 M | -4.84 M | -7.19 M | -9.52 M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
12.4 M | 13.9 M | 13.6 M | 7.88 M | 10.7 M | 7.72 M | 6.5 M | 4.91 M | 6.51 M | 7.16 M | 6.63 M | 4.71 M | 5.37 M | 8 M | 7.43 M | 6.35 M | 5.69 M | 4.04 M | 8.48 M | 11.1 M | 4.6 M | 4.68 M | 5.27 M | 4.57 M | 2.84 M | 4.2 M | 6.65 M | 6.4 M | 5.43 M | 6.62 M | 5.21 M | 4.87 M | 4.86 M | 11.3 M | 11.2 M | 13 M | 11.6 M | 12.6 M | 13.8 M | 13.4 M | 13.6 M | 14.8 M | 13.9 M | 11.3 M | 9.57 M | 8 M | 9.77 M | - | 5.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.9 M | 5.16 M | 4.6 M | 3.98 M | 3.68 M | 3.62 M | 3.67 M | 2.68 M | 3.28 M | 3.72 M | 3.98 M | 2.57 M | 2.54 M | 3.31 M | 3.48 M | 2.39 M | 2.63 M | 1.83 M | 5.35 M | 5.72 M | 2.22 M | 2.24 M | 2.16 M | 2.04 M | 1.07 M | 1.7 M | 2.45 M | 1.99 M | 1.77 M | 2.39 M | 2.39 M | 2.07 M | 2.16 M | 2.74 M | 2.26 M | 2.94 M | 2.57 M | 3 M | 2.82 M | 2.25 M | 2.4 M | 2.67 M | 2.58 M | 2.37 M | 2.42 M | 2.3 M | 2 M | - | 1.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company vTv Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Annexon
ANNX
|
$ 4.21 | 4.99 % | $ 653 M |  USA |
 |
AbbVie
ABBV
|
$ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
$ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
$ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
$ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
- | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
$ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
$ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
$ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
$ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
$ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
$ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
$ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
$ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
$ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
$ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
$ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | USA |
 |
Codexis
CDXS
|
$ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
$ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
$ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
$ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
- | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
$ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
- | - | - |  Russia |
 |
CorMedix
CRMD
|
$ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
$ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
$ 50.09 | 3.15 % | $ 4.5 B | Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
$ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
$ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
- | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
- | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
$ 7.93 | 0.51 % | $ 427 M | USA |